Investments
16Portfolio Exits
2Partners & Customers
5
Want to inform investors similar to Jointown Pharmaceutical Group about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Jointown Pharmaceutical Group News
Feb 24, 2021
02/24/2021 | 12:48am EST Message : Extensive cooperation across warehousing, domestic distribution, international transports and logistics In support of Chinese pharma customers' access to international markets, leveraging Kuehne+Nagel's global pharma network Further strengthens Kuehne+Nagel's presence in China Kuehne+Nagel announces a strategic partnership with Jointown, China's largest non-state-owned pharmaceutical distribution company, to accelerate its footprint in pharma and healthcare logistics in China. As one of the leading logistics providers in the world, Kuehne+Nagel has been especially focused on developing pharma & healthcare expertise for the past decade. The partnership with Jointown now affords access to their fullyGxP-compliant, in-country storage and distribution network, enabling Kuehne+Nagel to comply with the highly-regulated Chinese pharma & healthcare sector. 'We are pleased to be partnering with Jointown. Our cooperationperfectly meets the demands of our global clientele byenablingseamless supply chain coverage connecting China. This will enable us to accelerate our growth in the pharma and healthcare sector in China,' says Siewloong Wong, President of Kuehne+Nagel Asia Pacific. Zhang Qingsong, General Manager of the logistics business unit of Jointown Pharmaceutical Group, adds: 'Partnering with Kuehne+Nagel will provide Jointown's customers access to the international market through their global GxP certified air, sea and overseas contract logistics operations. We will now be able to expand our business in overseas markets at a much faster pace and benefit from the partnership in a sustainable way.' With Covid-19 vaccines becoming widely approved for use in more countries, Jointown and Kuehne+Nagel will collaborate to manage vaccine distribution in a safe and timely manner, leveraging their respective strengths in vaccine storage and distribution both in China and other parts of the world. Gianfranco Sgro, Member of the Management Board of Kuehne + Nagel International AG, responsible for Contract Logistics, says: 'Pharma & Healthcare is one of the fastest growing sectors in Contract Logistics. Kuehne+Nagel and Jointown share a common vision of service excellence for patients and customers in China and abroad'. The partnership with Jointown comes shortly after Kuehne+Nagel announced that it has entered into a binding agreement to acquire the Chinese company Apex International Corporation , one of Asia's leading freight forwarders. Latest news About Kuehne+Nagel With over 78,000 employees at 1,400 locations in over 100 countries, the Kuehne+Nagel Group is one of the world's leading logistics companies. Its strong market position lies in sea logistics, air logistics, road logistics and contract logistics, with a clear focus on integrated logistics solutions. About Jointown Jointown Pharmaceutical Group Co., Ltd. is a leading pharmaceutical company in China. Listed on the Shanghai Stock Exchange, Jointown is mainly responsible for supplying pharmaceutical drugs, traditional Chinese medicine (TCM), medical devices and consumer goods to clients including hospitals and clinics, retail pharmacies, wholesalers and government contracts. At the same time, Jointown provides e-commerce and online health management services to end users. Jointown Logistics, an affiliate of Jointown Pharmaceutical Group is a technology-based and environmentally-friendly logistics provider dedicated to serve the health industry. It provides customers with a wide range of integrated supply chain solutions supported by an extensive distribution network and advanced information technology capabilities. Attachments
Jointown Pharmaceutical Group Investments
16 Investments
Jointown Pharmaceutical Group has made 16 investments. Their latest investment was in Convalife as part of their Series B on January 1, 2023.

Jointown Pharmaceutical Group Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
1/3/2023 | Series B | Convalife | Yes | 1 | ||
12/27/2022 | Series D | First Bioscience | Yes | |||
7/11/2022 | Seed - II | Poclight Biological | $14.9M | Yes | Huatai Zijin Investment, Jointown Pharmaceutical Group, Nanjing New Industry Investment Group, and Wenzhou Investment | 1 |
6/9/2022 | Series B - II | |||||
4/19/2022 | Series B - II |
Date | 1/3/2023 | 12/27/2022 | 7/11/2022 | 6/9/2022 | 4/19/2022 |
---|---|---|---|---|---|
Round | Series B | Series D | Seed - II | Series B - II | Series B - II |
Company | Convalife | First Bioscience | Poclight Biological | ||
Amount | $14.9M | ||||
New? | Yes | Yes | Yes | ||
Co-Investors | Huatai Zijin Investment, Jointown Pharmaceutical Group, Nanjing New Industry Investment Group, and Wenzhou Investment | ||||
Sources | 1 | 1 |
Jointown Pharmaceutical Group Portfolio Exits
2 Portfolio Exits
Jointown Pharmaceutical Group has 2 portfolio exits. Their latest portfolio exit was Zhongke Tongda on July 13, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
7/13/2021 | IPO - II | Public | 1 | ||
Date | 7/13/2021 | |
---|---|---|
Exit | IPO - II | |
Companies | ||
Valuation | ||
Acquirer | Public | |
Sources | 1 |
Jointown Pharmaceutical Group Partners & Customers
5 Partners and customers
Jointown Pharmaceutical Group has 5 strategic partners and customers. Jointown Pharmaceutical Group recently partnered with Nippon Express on January 1, 2021.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
1/22/2021 | Partner | Japan | This business partnership will allow Nippon Express to offer services that meet customer needs for safety-conscious pharmaceutical transport by combining its own pharmaceutical logistics services utilizing its global network outside China with JPG 's domestic transport network within China . | 2 | |
8/28/2018 | Partner | ||||
8/28/2018 | Partner | ||||
3/10/2016 | Partner | ||||
1/11/2011 | Partner |
Date | 1/22/2021 | 8/28/2018 | 8/28/2018 | 3/10/2016 | 1/11/2011 |
---|---|---|---|---|---|
Type | Partner | Partner | Partner | Partner | Partner |
Business Partner | |||||
Country | Japan | ||||
News Snippet | This business partnership will allow Nippon Express to offer services that meet customer needs for safety-conscious pharmaceutical transport by combining its own pharmaceutical logistics services utilizing its global network outside China with JPG 's domestic transport network within China . | ||||
Sources | 2 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.